Vietnam import duties and taxes on drugs set to fall in bid to attract investment

15 October 2006

Vietnam's general tax levied on pharmaceuticals is to be gradually reduced from the present 0%-10% rate to 0%-0.5%, according to the government's Pharmaceutical Management Department. In addition, import duties on the 47 product categories of drugs that currently stand at 10%-15%, are due to be cut, as part of Vietnam's preparations to join the World Trade Organization.

Starting January 1, 2009, foreign drugmakers will be allowed to import and export drugs without having to employ local imntermediaries. Together with the reductions in taxes and import tariffs, the Vietnamese government hopes that the measures will improve the country's attractiveness to foreign drug firms.

Ly Ngoc Kinh, Director of the PMD's Therapeutic Department, said: "we should encourage foreign manufacturers to bring their technology, machines and people to Vietnam."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight